PHOTO
Dubai, United Arab Emirates: MSD, a leading global pharmaceutical company, has appointed Ashraf Malak as the Managing Director for the Gulf Cooperation Council cluster which includes Saudi Arabia, the United Arab Emirates, Kuwait, Bahrain, Qatar and Oman.
Most recently, Ashraf was the Regional Commercial Operations Director for MSD’s Eastern Europe, Middle East, and Africa region where he supported rapid market growth and digital transformation, also advancing the company’s capabilities within harnessing data analytics and implementing an all-new commercial strategy.
Prior to that, Ashraf was the Managing Director for MSD Saudi Arabia, transforming the company’s operations in the Kingdom and expanding patient access to novel oncology and vaccines therapies. He was instrumental within growing the business within acute care and cardiometabolic therapeutic areas, accelerating innovative drugs to local approval process and advancing the national vaccines program. Positioning MSD as an employer of choice, he also spearheaded the company’s talent management within the Kingdom, including accelerating the Saudization program.
Ashraf Malak, Managing Director, MSD, GCC said, “As a part of the MSD family for close to two decades, I will continue to support the team in delivering our scientific innovation and excellence within medicines and vaccines to save and improve lives. We will work along with the healthcare industry stakeholders to ensure greater patient access for new medicines to continue to be available. As we advance our therapeutic pipeline, we aim to fulfil unmet medical needs within our focus areas of oncology, vaccines, infectious diseases and diabetes disorders through impactful collaboration with GCC governments and industry partners.”
He added, “I would like to take the opportunity to thank Mazen Altaruti for his contributions for over 21 years in making MSD one of the top five pharmaceutical companies in the region. The team and I wish him the very best in the next chapter of his personal and professional goals.””
Ashraf joined MSD in UAE in 2002 and has held responsibilities within sales, marketing, market access, business unit management, commercial development, operations and general management. He holds a Bachelor of Science degree in Pharmaceutical Sciences from Jordan University and an MBA degree from the American University of Dubai, while also graduating from the Executive Leadership Program by Harvard Business School.
-Ends-
About MSD
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
MSD products has been present for over 30 years in the GULF region through its local distributors in the UAE, Kuwait, Bahrain, Qatar & Oman and MSD ranks amongst the leading pharmaceutical companies in the region. MSD provides innovative medications in several therapeutic areas, including Anti-Infectives, Diabetes, HCV, HIV, Oncology and Anesthesia in addition to several specialized Vaccines. For more information, visit www.msd.com and connect with us on Facebook, LinkedIn, YouTube and Twitter at MSD GCC.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
